Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: J Immunol. 2014 Aug 29;193(7):3816–3824. doi: 10.4049/jimmunol.1303256

Figure 1.

Figure 1

Single class II MHC-disparate renal allograft rejection by CCR5-deficient, but not wild type C567BL/6, recipients. Groups of wild type C57BL/6 and B6.CCR5−/− mice received single class II MHC disparate renal grafts from B6.H-2bm12 donors. (A) B6.CCR5−/− mice rejected the allografts within 40 days post-transplant (MST=28, n=11) whereas wild type recipients did not reject the allografts. (B) Serum creatinine levels in the renal allograft recipients were measured weekly after transplant and the mean serum concentration for each group is shown at each time point ± SEM. C57BL/6 kidney isografts were maintained by both wild type C57BL/6 and B6.CCR5−/− recipients long-term without any rise in serum creatinine levels (data not shown). *p < 0.05.